SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-022240
Filing Date
2023-06-15
Accepted
2023-06-15 16:23:27
Documents
15
Period of Report
2023-06-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20230615.htm   iXBRL 8-K 40321
2 EX-1.1 exhibit11-8xkoffering.htm EX-1.1 201993
3 EX-5.1 exhibit51-8xkoffering.htm EX-5.1 21793
7 lathamandwatkinslogo.jpg GRAPHIC 77458
  Complete submission text file 0001628280-23-022240.txt   557463

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20230615.xsd EX-101.SCH 1904
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20230615_lab.xml EX-101.LAB 24851
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20230615_pre.xml EX-101.PRE 13048
9 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20230615_htm.xml XML 11306
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 231017674
SIC: 2834 Pharmaceutical Preparations